XNK Therapeutics AB (“XNK”) today announced it has become a partner in Swelife’s health economics project on Advanced Therapy Medicinal Products (ATMP).
The partnership allows the company to develop its technology within the Swelife ATMP organization. The main objective of the project is to stimulate and promote growth within the Swedish ATMP sector by nationally developing associated skills in process development and commercial challenges and making them available on a broader scale.
Swelife supports collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health. It is a strategic innovation program, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the program’s partners.
For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit xnktherapeutics.com.
About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.
